CARMA Advances Funding for Development of Immunotherapy Program to Treat Metastatic Solid Tumors

CARMA Advances Funding for Development of Immunotherapy Program to Treat Metastatic Solid Tumors
CARMA Therapeutics has closed an initial financing, co-led by AbbVie Ventures and HealthCap, to build a pipeline of cancer programs using its proprietary chimeric antigen receptor targeting with macrophages (CARMA) platform to tackle solid tumors. The Philadelphia-based company will use proceeds mainly to develop its first product, CARMA-0508, an adoptive cellular immunotherapy designed to treat metastatic

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *